Article Information
History
- December 20, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Joann F. Gruber, PhD, MSPHa,*,
- Kathryn Matuska, BAb,
- Carla E. Zelaya, PhD, MSca,
- Jing Wang, BAb,
- Cheryl N McMahill-Walraven, PhD, MSWc,
- Lauren Peetluk, PhD, MPHd,
- Alex Secora, PhDe,
- Shwetha Krishnakumar, BAb,
- Mao Hu, BSb,
- Kandace L. Amend, PhD, MPHd,
- Jennifer Song, MA, MURPd,
- Daniel C. Beachler, PhD, MHSf,
- Patricia C. Lloyda, PhD, ScM,
- Yoganand Chillarige, MPAb,
- Jane A. Gwira, MD, MPHa,
- Wafa Tarazi, PhD, MHPAg,
- Tainya C. Clarke, PhD, MPH, MSca,
- Djeneba Audrey Djibo, PhDc,
- Richard A. Forshee, PhDa,
- Azadeh Shoaibi, PhD, MHSa and
- Steven A. Anderson, PhD, MPPa
- aU.S. Food and Drug Administration, Silver Spring, MD, USA
- bAcumen LLC, Burlingame, CA, USA
- cCVS Health, Blue Bell, PA, USA
- dOptum Epidemiology, Boston, MA, USA
- eIQVIA, Falls Church, VA, USA
- fCarelon Research, Wilmington, DE, USA
- gOptumServe, Falls Church, VA, USA
- ↵*Corresponding Author:
Joann F. Gruber, PhD, MSPH, Epidemiologist, Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71 Silver Spring, MD 20993, Email: Joann.Gruber{at}fda.hhs.gov
Posted December 20, 2024.
Safety Monitoring of Mpox Vaccines in Adults Aged 18–64 Years during the 2022 Mpox Outbreak in the U.S.
